SMD/ATG-CSA: Antithymocyte globulin and cyclosporine in treating low risk patients with myelodysplastic syndrome

Trial Profile

SMD/ATG-CSA: Antithymocyte globulin and cyclosporine in treating low risk patients with myelodysplastic syndrome

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2013

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Ciclosporin (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Apr 2008 Trial end date is Dec 2008.
    • 15 Apr 2008 Status changed from recruiting to completed according to clinicaltrials.gov record.
    • 17 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top